Press Releases
Samsung Biologics named winner of 2025 CDMO Leadership Awards
Samsung Biologics received the CDMO Leadership Awards presented by Outsourced Pharma. The company was named a winner in the ‘Biologics – Global’ category and also received the “Best Facility” award this year. Samsung Biologics has received the CDMO leadership award for 12 consecutive years.
The CDMO Leadership Awards recognize top-performing development and manufacturing service providers based on global client feedback in various areas such as facilities, innovation, technical expertise, and manufacturing capabilities.
“We are grateful to receive the recognition and appreciate our clients and partners for the trust and confidence they have in our services and capabilities,” said John Rim, CEO and President of Samsung Biologics. “The award underscores our commitment to deliver high-quality biomedicines and maximize client satisfaction by prioritizing quality and operational excellence at all times.”
“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the Outsourcing community, and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Louis Garguilo, Chief Editor of Outsourced Pharma. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs.”
Samsung Biologics continues to build on its capabilities and expand its capacity to readily address the evolving needs of clients." The company's fifth plant will become operational next month, bringing the total capacity to 784,000 liters. Samsung Biologics has also diversified its portfolio by providing end-to-end ADC services at a dedicated facility in Songdo.
Samsung Biologics received the CDMO Leadership Awards presented by Outsourced Pharma. The company was named a winner in the ‘Biologics – Global’ category and also received the “Best Facility” award this year. Samsung Biologics has received the CDMO leadership award for 12 consecutive years.
The CDMO Leadership Awards recognize top-performing development and manufacturing service providers based on global client feedback in various areas such as facilities, innovation, technical expertise, and manufacturing capabilities.
“We are grateful to receive the recognition and appreciate our clients and partners for the trust and confidence they have in our services and capabilities,” said John Rim, CEO and President of Samsung Biologics. “The award underscores our commitment to deliver high-quality biomedicines and maximize client satisfaction by prioritizing quality and operational excellence at all times.”
“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the Outsourcing community, and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Louis Garguilo, Chief Editor of Outsourced Pharma. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs.”
Samsung Biologics continues to build on its capabilities and expand its capacity to readily address the evolving needs of clients." The company's fifth plant will become operational next month, bringing the total capacity to 784,000 liters. Samsung Biologics has also diversified its portfolio by providing end-to-end ADC services at a dedicated facility in Songdo.